RRAD and GEM like GTPase 1Genealiases: GD:REM · GES
Q-omics provides the consensus-scored REM1 profile across patient tissues and cancer cell-line models. REM1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, REM1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, REM1 RNA expression shows 16,967 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUAD, and LSCC as cancer lineages where REM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REM1 survival associations across molecular data types. REM1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REM1 RNA expression–survival associations across cancer types. High REM1 expression shows unfavorable associations in KIRP, UVM and ACC, but favorable associations in HNSC, SKCM and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for REM1 RNA expression.
This table summarizes REM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for REM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REM1 shows lower tumor expression in LUAD, KICH, LUSC, BLCA, KIRP and UCEC. The LUAD box plot shows higher REM1 RNA expression in normal versus tumor tissue (log2 FC = −1.478, t-test p < 0.001).
This table shows molecular features associated with REM1 in patient tissues and cancer cell lines. In patient samples, REM1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, REM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
